Cardiovascular safety of dipeptidyl peptidase-4 inhibitors

Recent evidence on heart failure

Saumya Reddy Kankanala, Rafay Syed, Quan Gong, Boxu Ren, Xiaoquan Rao, Jixin Zhong

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

The cardiovascular safety of DPP4 inhibitors as a class, especially in regards to heart failure, has been questioned after the publication of first trials (SAVOR-TIMI 53 and EXAMINE) assessing the cardiovascular risks of DPP4 inhibitors alogliptin and sitagliptin in 2013. Although there were no increased risks in composite cardiovascular outcomes, the SAVOR-TIMI 53 trial reported a 27% increase in hospitalization for heart failure in diabetic patients who received the DPP4 inhibitor saxagliptin. There has been substantial increase in knowledge on the heart failure effect of DPP4 inhibition since 2013. This review will summarize the role of the DPP4/incretin axis in heart failure and discuss the findings from recent large scale clinical trials assessing the effects of DPP4 inhibitors on heart failure.

Original languageEnglish (US)
Pages (from-to)2450-2458
Number of pages9
JournalAmerican Journal of Translational Research
Volume8
Issue number5
StatePublished - Jan 1 2016
Externally publishedYes

Fingerprint

Dipeptidyl-Peptidase IV Inhibitors
Heart Failure
Safety
Incretins
Publications
Hospitalization
Clinical Trials
Composite materials

Keywords

  • Cardiovascular outcomes
  • Dpp4
  • Heart failure
  • Incretin

ASJC Scopus subject areas

  • Molecular Medicine
  • Clinical Biochemistry
  • Cancer Research

Cite this

Cardiovascular safety of dipeptidyl peptidase-4 inhibitors : Recent evidence on heart failure. / Kankanala, Saumya Reddy; Syed, Rafay; Gong, Quan; Ren, Boxu; Rao, Xiaoquan; Zhong, Jixin.

In: American Journal of Translational Research, Vol. 8, No. 5, 01.01.2016, p. 2450-2458.

Research output: Contribution to journalArticle

Kankanala, Saumya Reddy ; Syed, Rafay ; Gong, Quan ; Ren, Boxu ; Rao, Xiaoquan ; Zhong, Jixin. / Cardiovascular safety of dipeptidyl peptidase-4 inhibitors : Recent evidence on heart failure. In: American Journal of Translational Research. 2016 ; Vol. 8, No. 5. pp. 2450-2458.
@article{c4bc1d416d7c4c98b07a829f705f70c7,
title = "Cardiovascular safety of dipeptidyl peptidase-4 inhibitors: Recent evidence on heart failure",
abstract = "The cardiovascular safety of DPP4 inhibitors as a class, especially in regards to heart failure, has been questioned after the publication of first trials (SAVOR-TIMI 53 and EXAMINE) assessing the cardiovascular risks of DPP4 inhibitors alogliptin and sitagliptin in 2013. Although there were no increased risks in composite cardiovascular outcomes, the SAVOR-TIMI 53 trial reported a 27{\%} increase in hospitalization for heart failure in diabetic patients who received the DPP4 inhibitor saxagliptin. There has been substantial increase in knowledge on the heart failure effect of DPP4 inhibition since 2013. This review will summarize the role of the DPP4/incretin axis in heart failure and discuss the findings from recent large scale clinical trials assessing the effects of DPP4 inhibitors on heart failure.",
keywords = "Cardiovascular outcomes, Dpp4, Heart failure, Incretin",
author = "Kankanala, {Saumya Reddy} and Rafay Syed and Quan Gong and Boxu Ren and Xiaoquan Rao and Jixin Zhong",
year = "2016",
month = "1",
day = "1",
language = "English (US)",
volume = "8",
pages = "2450--2458",
journal = "American Journal of Translational Research",
issn = "1943-8141",
publisher = "e-Century Publishing Corporation",
number = "5",

}

TY - JOUR

T1 - Cardiovascular safety of dipeptidyl peptidase-4 inhibitors

T2 - Recent evidence on heart failure

AU - Kankanala, Saumya Reddy

AU - Syed, Rafay

AU - Gong, Quan

AU - Ren, Boxu

AU - Rao, Xiaoquan

AU - Zhong, Jixin

PY - 2016/1/1

Y1 - 2016/1/1

N2 - The cardiovascular safety of DPP4 inhibitors as a class, especially in regards to heart failure, has been questioned after the publication of first trials (SAVOR-TIMI 53 and EXAMINE) assessing the cardiovascular risks of DPP4 inhibitors alogliptin and sitagliptin in 2013. Although there were no increased risks in composite cardiovascular outcomes, the SAVOR-TIMI 53 trial reported a 27% increase in hospitalization for heart failure in diabetic patients who received the DPP4 inhibitor saxagliptin. There has been substantial increase in knowledge on the heart failure effect of DPP4 inhibition since 2013. This review will summarize the role of the DPP4/incretin axis in heart failure and discuss the findings from recent large scale clinical trials assessing the effects of DPP4 inhibitors on heart failure.

AB - The cardiovascular safety of DPP4 inhibitors as a class, especially in regards to heart failure, has been questioned after the publication of first trials (SAVOR-TIMI 53 and EXAMINE) assessing the cardiovascular risks of DPP4 inhibitors alogliptin and sitagliptin in 2013. Although there were no increased risks in composite cardiovascular outcomes, the SAVOR-TIMI 53 trial reported a 27% increase in hospitalization for heart failure in diabetic patients who received the DPP4 inhibitor saxagliptin. There has been substantial increase in knowledge on the heart failure effect of DPP4 inhibition since 2013. This review will summarize the role of the DPP4/incretin axis in heart failure and discuss the findings from recent large scale clinical trials assessing the effects of DPP4 inhibitors on heart failure.

KW - Cardiovascular outcomes

KW - Dpp4

KW - Heart failure

KW - Incretin

UR - http://www.scopus.com/inward/record.url?scp=84971659588&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84971659588&partnerID=8YFLogxK

M3 - Article

VL - 8

SP - 2450

EP - 2458

JO - American Journal of Translational Research

JF - American Journal of Translational Research

SN - 1943-8141

IS - 5

ER -